HUG project leader Patrick Petignat, Rosa Catarino,
Department, division Département de Gynécologie et Obstétrique / Département de Gynécologie et Obstétrique /
e-mail patrick.petignat@hcuge.ch, RosaIsabel.PintoCatarino@hcuge.ch,
Country partner Cameroun
Project partner abroad Kenfack Bruno, Pierre-Marie Tebeu, Adamo Bongoe
Department, division Unité de Santé Reproductive / Département d'obstétrique et gynécologie / Département d'obstétrique et gynécologiec
Institution Hopital de District Dschang / Hôpital du Centre Hospitalier Universitaire de Yaoundé / Hopital Regional Edea
e-mail brunokenfack@gmail.com, pmtebeu@yahoo.fr, bongoecam@yahoo.com
Starting date 01/07/2015
Ending date
Cervical cancer is a significant reproductive health problem and the leading cause of cancer death among women in sub-Saharan Africa. Human papillomavirus (HPV) rapid test offers the opportunity to prevent cervical cancer in a single visit. Our goal is to to assess the feasibility and safety to prevent cervical cancer using rapid HPV test.
Study site will be a geographically well-defined area in West Region Cameroon (Dschang) with an estimated population of 250,000 inhabitants. Eligible women, aged between 30 and 49, will be invited to perform a rapid HPV self-test (Xpert HPV). HPV-negative women will be reassured and counseled to repeat the test in 5 to 10 years. HPV-positive women will be invited for visual inspection with acetic acid and Lugol (VIA/VILI) and therapy if abnormal. Quality control will be assessed using (i) histology of abnormal results, and (ii) a set of digital photographs of the cervix. Sensitivity, specificity, positive predictive value and negative predictive value will be calculated for the VIA/VILI using histopathology as gold standard. The pictures of the cervix will be analyzed by specialists in Geneva, as part of a telemedicine project.
The availability of a rapid HPV self-test provides an unprecedented opportunity to develop a cervical cancer screening programme in a population with low or medium resources in a single-visit approach. The study will also determine the level of support which is needed to implement and maintain high-quality HPV-based cervical cancer detection.